摘要Gastric cancer is one of the most prevalent cancers worldwide,and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20％of the total cases.Currently,trastuzumab+chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer,and the combination has exhibited definite efficacy in HER2-targeted therapy.However,the emergence of drug resistance during treatment considerably reduces its effectiveness;thus,it is imperative to investigate the potential mechanisms underlying resistance.In the present review article,we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases,aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.
作者单位Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer,Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer,Zhengzhou 450008,China[1]Henan University of Traditional Chinese Medicine,Zhengzhou 450046,China[2]State Key Laboratory of Esophageal Cancer Prevention & Treatment,Key Laboratory of Advanced Drug Preparation Technologies,Ministry of Education,School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China[3]The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453000,China[4]Department of Oncology,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou 450008,China[5]
换一批
